<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148036">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01966887</url>
  </required_header>
  <id_info>
    <org_study_id>P081252</org_study_id>
    <nct_id>NCT01966887</nct_id>
  </id_info>
  <brief_title>AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure</brief_title>
  <acronym>AGENT-HF</acronym>
  <official_title>Phase 2 Study of SERCA2a Gene Transfer in Patients With Severe Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celladon Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of intracoronary SERCA2a Gene transfer
      on cardiac volumes and function using multimodality cardiac imaging.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of gene transfer of SERCA2a is to improve systolic and diastolic function of the
      failing ventricle. Studies show that reduction of SERCA2a in failing ventricle is a key
      factor in depression of contraction, and that restoration of SERCA2a levels can improve left
      ventricular function and remodeling. The aim of the study is to investigate the effect of an
      adeno-associated viral vector expressing the sarcoplasmic reticulum calcium ATPase
      (SERCA2a), driven by the CMV promoter (AAV1-CMV-SERCA2a), on the ventricular remodeling of
      patients with severe heart failure using multimodality cardiac imaging. This is a Phase 2
      monocenter double blind randomized placebo-controled, parallel study. The study will enroll
      44 symptomatic heart failure patients with NYHA IIIb/IV, with left-ventricular ejection
      fraction of 35% or less receiving an optimal standard medical therapy. The absence of
      neutralizing antibodies against AAV1 will be primarily checked. Seronegative patients will
      be randomized to receive either 1x10e13 AAV1-CMV-Serca2a or a placebo as a single
      intracoronary infusion. Evolution during the next 6 months of the left ventricular
      end-systolic volume (measured with a 256-slices CT-scan before injection and 6 months later)
      will be the primary endpoint. Secondary endpoints will include changes in the LVEF,
      diastolic volumes, VO2max, Echocardiographic remodeling, BNP, cardiac hemodynamics and
      biological safety profile.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>left ventricular end-diastolic volume measured by CT-Scan</measure>
    <time_frame>at 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>left ventricular end-diastolic volume measured by CT-Scan / changes from baseline to 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CT-scan other measurments: left ventricular and diastolic volume</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>CT-scan other measurments: left ventricular and diastolic  volume / changes from baseline to 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac volumes and function</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cardiac volumes and function / changes from baseline to 6 months &amp; 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac hemodynamic parameters</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cardiac hemodynamic parameters; changes from baseline to 6 &amp; 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VO2 max</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>VO2 max; changes from baseline to 6 months and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function assessed by echocardiography</measure>
    <time_frame>at 3,6,9,12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes from baseline to 3,6,9,12 months in:Echocardiographic assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (Kansas city score)</measure>
    <time_frame>at 3,6,9,12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes from baseline to 3,6,9,12 months in:Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-ProBNP</measure>
    <time_frame>at 3,6,9,12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes from baseline to 3,6,9,12 months in:NT-ProBNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to cardiovascular event</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to cardiovascular event (all-cause death, heart transplant, LVAD implantation) - administration to 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalized patients for worsening heart failure</measure>
    <time_frame>at 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac volumes assessed by echocardiography</measure>
    <time_frame>at 3,6,9,12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes from baseline to 3,6,9,12 months in:Echocardiographic assessments</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Heart Failure Congestive</condition>
  <condition>Ischemic Cardiomyopathy</condition>
  <condition>Non-ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>MYDICAR-single intracoronary infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genetic / AAV1 Serca2a (MYDICAR)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo; single intracoronary infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>MYDICAR-single intracoronary infusion</intervention_name>
    <description>AAV1/Serca2a</description>
    <arm_group_label>MYDICAR-single intracoronary infusion</arm_group_label>
    <other_name>1x10e13 DRP; single intracoronary infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Placebo; single intracoronary infusion</intervention_name>
    <description>single intracoronary infusion</description>
    <arm_group_label>Placebo; single intracoronary infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with NYHA class III / IV severe heart failure ≥ 3 months

          -  Ischemic or non-ischemic origin

          -  Left ventricular ejection fraction ≤35%

          -  Patients must be receiving optimal (maximum tolerated doses) medical treatment
             (diuretics, renin-angiotensin-aldosterone system blockers, beta blockers,
             ±Ivabradine) for at least 1 month (with the exception of diuretic dose titration) and
             must be stable.

          -  No decompensated heart failure within the past month

          -  With or without an ICD, with or without biventricular pacing if the ICD was implanted
             over 6 months ago

          -  All women of childbearing potential must have a negative urine pregnancy test prior
             to administration of investigational medicinal product

          -  Patient must have given written informed consent to participate in this study

        Exclusion Criteria:

          -  &lt;18 or &gt;80 years old

          -  AAV1 seropositivity (titer &lt;1:2) in the last 3 months

          -  Atrial fibrillation

          -  Coronary revascularization or heart surgery &lt; 3 months

          -  Ischemic heart disease without at least one coronary artery with a TIMI-3 flow

          -  Restrictive cardiomyopathy, hypertrophic obstructive cardiomyopathy, pericardial
             disease, cardiac amyloidosis

          -  Heart transplant, an already implanted or needing to urgently implant external
             ventricular assist device

          -  Myocardial infarction (STEMI or NSTEMI) &lt; 3 months

          -  Treatment with intravenous positive inotropic agents or diuretics in the past 28 days

          -  Pregnant or nursing patient

          -  Female patient of childbearing age with no effective means of contraception

          -  Severe renal failure defined by a creatinine clearance of &lt; 30 mL/min (last bloodwork
             done less than 6 months)

          -  Liver failure, chronic liver disease or laboratory tests &gt; 3 x N (AST, ALT,
             ALP))(last bloodwork done less than 6 months)

          -  Thrombocytopenia (&lt;50,000/mm3

          -  Patient treated with immunosuppressants, has an immunodeficiency or whose neutrophil
             count &lt; 1000 mm3

          -  Recent sepsis (&lt; 3 months)

          -  No medical insurance

          -  Patient is enrolled in another randomized study

          -  Patient does not understand the protocol procedures sponsor suspects poor compliance
             with the protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Sébastien HULOT, MDPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Sébastien HULOT, MD PhD</last_name>
    <phone>+33 1 42 16 29 59</phone>
    <email>jean-sebastien.hulot@psl.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Sébastien HULOT, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 11, 2014</lastchanged_date>
  <firstreceived_date>September 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>Serca2a</keyword>
  <keyword>Cardiomyopathy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
